About the Authors

Aaron D. Schimmer

aaron.schimmer@utoronto.ca

Affiliation Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Azra Raza

Affiliation Columbia University Medical Center, New York, New York, United States of America

Thomas H. Carter

Affiliation The University of Iowa, Iowa City, Iowa, United States of America

David Claxton

Affiliation Penn State, Hershey, Pennsylvania, United States of America

Harry Erba

Affiliation University of Alabama at Birmingham, Birmingham, Alabama, United States of America

Daniel J. DeAngelo

Affiliation Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

Martin S. Tallman

Affiliation Leukemia Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York, United States of America

Carolyn Goard

Affiliation Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Gautam Borthakur

Affiliation The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Competing Interests

The authors have read the journal's policy and have the following competing interests: ADS, GB, and THC report research support from GeminX, during the conduct of the study; HE reports compensation from Celgene, Novartis, Celator, Sunesis, Seattle Genetics, and Incyte, outside the submitted work; AR, DC, DJD, CG, and MST have no competing interests to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: ADS GB. Performed the experiments: ADS AR THC DC HE DJD MST CG GB. Analyzed the data: ADS AR THC DC GB. Contributed reagents/materials/analysis tools: ADS AR THC DC HE DJD MST GB. Wrote the paper: ADS AR THC HE DJD MST CG.